New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
- PMID: 28583618
- DOI: 10.1016/j.chest.2017.05.019
New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
Abstract
Asthma and COPD are prevalent chronic inflammatory airway diseases that are responsible for a large global disease burden. Both diseases are complex and heterogeneous, and they are increasingly recognized as overlapping syndromes that may share similar pathophysiologic mechanisms and treatable traits. Eosinophilic airway inflammation is considered the most influential treatable trait of chronic airway disease, and over the last decade, several monoclonal antibodies and small molecule therapies have been developed to target this trait. These include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin D2 blockers (fevipiprant and timapiprant). Although these novel biologic agents have shown promising results in many patients with asthma and COPD who have eosinophilic airway inflammation, it is evident that not all patients respond equally well, despite similar clinical, functional, and inflammatory characteristics. This heterogeneity in treatment response is probably related to different molecular pathways or endotypes leading to eosinophilic airway inflammation, including adaptive immune pathways mediated by T helper 2 cells and innate immune pathways mediated by innate lymphoid cells. The relative contribution of these pathways in asthma and COPD is not yet clarified, and there are currently no reliable biomarkers that represent the various pathways. Therefore, there is an urgent need for easily measurable and reproducible biomarkers that are linked to underlying pathophysiologic disease mechanisms and can predict and monitor responses to novel biologic agents.
Keywords: COPD; airway inflammation; asthma; eosinophils; pharmacotherapy.
Copyright © 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Molecular Targets for Biological Therapies of Severe Asthma.Front Immunol. 2020 Nov 30;11:603312. doi: 10.3389/fimmu.2020.603312. eCollection 2020. Front Immunol. 2020. PMID: 33329598 Free PMC article. Review.
-
Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.Respir Res. 2019 Jan 18;20(1):14. doi: 10.1186/s12931-018-0968-8. Respir Res. 2019. PMID: 30658649 Free PMC article. Clinical Trial.
-
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.Drug Des Devel Ther. 2018 Mar 21;12:619-628. doi: 10.2147/DDDT.S155307. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 29606855 Free PMC article. Review.
-
Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.J Allergy Clin Immunol. 2015 Sep;136(3):531-45. doi: 10.1016/j.jaci.2015.05.052. J Allergy Clin Immunol. 2015. PMID: 26343937 Review.
-
Monoclonal antibodies for the treatment of refractory asthma.Curr Opin Pulm Med. 2014 Jan;20(1):87-94. doi: 10.1097/MCP.0000000000000007. Curr Opin Pulm Med. 2014. PMID: 24275927 Review.
Cited by
-
Relationship between triglyceride-glucose index and blood eosinophils among asthmatic individuals in the USA.Lipids Health Dis. 2024 May 21;23(1):149. doi: 10.1186/s12944-024-02136-7. Lipids Health Dis. 2024. PMID: 38773617 Free PMC article.
-
Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease.Front Med (Lausanne). 2024 Feb 13;11:1334442. doi: 10.3389/fmed.2024.1334442. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38414617 Free PMC article.
-
Blood Eosinophil Count and Its Determinants in a Chinese Population-Based Cohort.Respiration. 2024;103(2):70-78. doi: 10.1159/000535989. Epub 2024 Jan 22. Respiration. 2024. PMID: 38253034 Free PMC article.
-
The Role of Eosinophil-Derived Neurotoxin and Vascular Endothelial Growth Factor in the Pathogenesis of Eosinophilic Asthma.Cells. 2023 May 6;12(9):1326. doi: 10.3390/cells12091326. Cells. 2023. PMID: 37174726 Free PMC article. Review.
-
Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice.Int J Mol Sci. 2023 Apr 14;24(8):7254. doi: 10.3390/ijms24087254. Int J Mol Sci. 2023. PMID: 37108417 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical